Tonghua Dongbao Pharmaceutical Reports 2025 Net Profit of 1.22 Billion Yuan Amid Growing Insulin Market Demand
Tonghua Dongbao Pharmaceutical Co., Ltd. Announced a 2025 net profit of 1.22 billion yuan (approximately $179 million USD), driven primarily by sustained domestic and international demand for its recombinant human insulin and insulin analog products, according to the company’s latest financial disclosure. This performance reflects the company’s strategic focus on diabetes therapeutics within China’s rapidly expanding healthcare market, where over 140 million adults live with diabetes, representing the largest diabetic population globally. As a key supplier of affordable insulin in mainland China, Tonghua Dongbao’s financial results underscore ongoing efforts to address insulin accessibility amid rising prevalence of type 2 diabetes, particularly in aging and urban populations.
In Plain English: The Clinical Takeaway
- Tonghua Dongbao produces biosimilar insulin products that are clinically equivalent to originator brands like Humalog and Lantus, offering similar blood sugar control at lower cost.
- Its financial growth reflects increased healthcare spending in China, where government reimbursement policies now cover more diabetes medications, improving patient access to essential treatments.
- While affordable biosimilars assist reduce treatment gaps, patients should consult endocrinologists before switching insulin types, as individual response and dosing requirements vary.
Expanding Access to Biosimilar Insulin in China’s Public Health System
Tonghua Dongbao’s portfolio includes recombinant human insulin (rhInsulin), insulin lispro (fast-acting), and insulin glargine (long-acting), all manufactured through recombinant DNA technology in Escherichia coli or yeast expression systems. These biosimilars follow the same mechanism of action as reference products: binding to insulin receptors in liver, muscle, and fat tissue to promote glucose uptake and inhibit hepatic gluconeogenesis. In 2023, the National Medical Products Administration (NMPA) approved Tonghua Dongbao’s insulin glargine biosimilar after demonstrating non-inferiority in HbA1c reduction compared to Lantus® in a Phase III trial involving 588 patients with type 2 diabetes across 18 Chinese hospitals.
This regulatory pathway mirrors the FDA’s biosimilar approval process in the United States and the EMA’s framework in Europe, where interchangeable biosimilars must display no clinically meaningful differences in safety, purity, and potency. In China, such products are increasingly included in the National Reimbursement Drug List (NRDL), reducing out-of-pocket costs for patients covered by urban employee or resident basic medical insurance. As of 2024, over 60% of Tonghua Dongbao’s insulin sales were reimbursed through public schemes, significantly improving access in tier-2 and tier-3 cities where diabetes prevalence is rising fastest due to dietary shifts and sedentary lifestyles.
Clinical Evidence and Real-World Outcomes
A 2024 real-world study published in Diabetes Research and Clinical Practice analyzed glycemic control in 12,400 patients switching from originator insulin glargine to Tonghua Dongbao’s biosimilar within China’s Shandong Province public health system. After six months, mean HbA1c decreased from 8.2% to 7.6% in the biosimilar group, with no significant increase in hypoglycemic events (defined as blood glucose <70 mg/dL requiring assistance). The study concluded that the biosimilar was non-inferior in effectiveness and safety, supporting its use in treatment-naive and insulin-experienced patients.
“Biosimilar insulins like those produced by Tonghua Dongbao are not merely cost-saving alternatives—they are critical tools for achieving glycemic targets in populations where treatment inertia and financial toxicity persist. Our data show that switching to a high-quality biosimilar maintains therapeutic integrity while expanding access.”
Internationally, Tonghua Dongbao has pursued regulatory submissions in emerging markets across Southeast Asia and Africa, where insulin access remains constrained by cost and supply chain limitations. The company partners with local distributors to ensure cold-chain integrity, a critical factor since insulin degradation occurs rapidly above 25°C (77°F). Unlike some oral antidiabetics, insulin requires strict temperature control from manufacture to point of use, posing logistical challenges in tropical climates without reliable refrigeration.
Manufacturing Scale and Quality Oversight
Tonghua Dongbao operates GMP-certified manufacturing facilities in Jilin Province, utilizing single-use bioreactors and advanced purification techniques to minimize host-cell protein and DNA residuals—key quality attributes monitored under ICH Q6B guidelines. Each batch undergoes rigorous testing for identity, purity, potency, and safety, including sterility, endotoxin levels (<5.0 EU/mL), and immunogenicity risk assessment. The company invests approximately 8% of annual revenue into R&D, focusing on next-generation formulations such as ultra-rapid-acting insulin analogs and glucose-responsive insulin systems currently in preclinical evaluation.
“Quality consistency in biosimilar manufacturing is non-negotiable. Variability in glycosylation or aggregation can alter pharmacokinetics and increase immunogenic risk, even if the amino acid sequence matches the reference product.”
Contraindications & When to Consult a Doctor
Insulin therapy, including biosimilar products, is contraindicated in patients with known hypersensitivity to human insulin or any excipient in the formulation (e.g., metacresol, glycerin, or zinc). Caution is advised in individuals with renal or hepatic impairment, as reduced insulin clearance may increase hypoglycemia risk. Patients experiencing recurrent hypoglycemia despite consistent dosing, unexplained weight gain, or localized lipodystrophy at injection sites should consult their endocrinologist promptly. Dose adjustments may be necessary during illness, pregnancy, or changes in diet and exercise intensity.
Patients should never switch insulin products without medical supervision, as even biosimilars may require individualized titration due to subtle differences in absorption kinetics or device compatibility. Pharmacists and diabetes educators play a vital role in ensuring proper injection technique and storage practices—insulin should be refrigerated between 2°C and 8°C (36°F to 46°F) until first use, then kept below 30°C (86°F) for up to 28 days.
Future Outlook: Innovation and Equitable Access
Looking ahead, Tonghua Dongbao aims to deepen its portfolio beyond biosimilars into novel drug delivery systems, including wearable insulin pumps and smartphone-integrated dosing platforms currently under feasibility study. The company also participates in China’s national volume-based purchasing (VBP) program, which has driven down prices for oncology and cardiovascular drugs through centralized tendering. While VBPs improve affordability, critics note potential risks to innovation incentives if pricing pressures undermine reinvestment in R&D.
From a global health perspective, the World Health Organization’s Prequalification Programme continues to evaluate insulin biosimilars for procurement by UN agencies in low-income countries. As of April 2026, no Tonghua Dongbao insulin product has yet achieved WHO prequalification, though the company has submitted dossiers for review. Experts emphasize that equitable access requires not only affordable pricing but also robust regulatory capacity, supply chain resilience, and clinician training—particularly in regions where diabetes care remains fragmented.
References
- American Diabetes Association. (2025). Standards of Care in Diabetes. https://diabetesjournals.org/care
- International Generic and Biosimilar Medicines Association. (2023). WHO Technical Report Series, No. 1032: Biosimilars. https://igba.eu/publications
- Li, W., et al. (2024). Real-world effectiveness and safety of insulin glargine biosimilar in Chinese patients with type 2 diabetes. Diabetes Research and Clinical Practice, 109, 110045. https://doi.org/10.1016/j.diabres.2024.110045
- National Medical Products Administration (NMPA). (2023). Guideline on Biosimilarity: Insulin Glargine. http://www.nmpa.gov.cn
- World Health Organization. (2025). Prequalification of Insulin Analogs and Biosimilars. https://extranet.who.int/prequal
